Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Leyton, Yessica ^a   Gonzalez Hormazabal, Patricio ^a   Blanco, Rafael ^a   Bravo, Teresa ^b   Fernandez Ramires, Ricardo ^c   Morales, Sebastian ^a   Landeros, Natalia ^a   Reyes, Jose M ^d   Peralta, Octavio ^a,d   Tapia, Julio C ^a   Gomez, Fernando ^e   Waugh, Enrique ^e   Ibañez, Gladys ^f,g   Pakomio, Janara ^a   Grau, Gilberto ^a   Jara, Lilian ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b National Cancer Society Corporacion Nacional del Cancer CONAC   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d Clínca Las Condes   (Chile)

^e CLÍNICA SANTA MARÍA   (Chile)

^f Section of Gastroenterology   (Chile)

^g HOSPITAL SAN JOSÉ   (Chile)

Author keywords

BRCA1 2 negative families; Familial breast cancer; PALB2; South American population

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA; ONCOPROTEIN; PARTNER AND LOCALIZER OF BRCA2 PROTEIN; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER RISK; CHILEAN; CONTROLLED STUDY; EARLY CANCER; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GEL ELECTROPHORESIS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PALB2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; ALLELE; BIOLOGY; BREAST NEOPLASMS; CASE CONTROL STUDY; CHILE; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOTYPE; HEALTH SURVEY; MIDDLE AGED; MUTATION; ONSET AGE; PREVALENCE; RISK; YOUNG ADULT;

ADULT; AGE OF ONSET; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHILE; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POPULATION SURVEILLANCE; PREVALENCE; RISK; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84924029680     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1033-3     Document Type: Article

References (56)

1. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11:103-5.
2. Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, et al. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res. 2008;14:5931-7.
3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719-24.
4. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719-29.
5. Sy SMH, Huen MSY, Chen JJ. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A. 2009;106:7155-60.
6. Zhang F, Ma JL, Wu JX, Ye L, Cai H, Xia B, et al. PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr Biol. 2009;19:524-9.
7. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res. 2009;7:1110-8.
8. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162-4.
9. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165-7.
10. Erkko H, Xia B, Nikkilae J, Schleutker J, Syrjaekoski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316-9.
11. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9(6):R83.
12. Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res. 2010;12(6):R109.
13. Erkko H, Dowty JG, Nikkila J, Syrjakoski K, Mannermaa A, Pylkas K, et al. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res. 2008;14:4667-71.
14. Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev. 2010;20:268-76.
15. Phuah SY, Lee SY, Kang P, Kang IN, Yoon SY, Thong MK, et al. Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore. PLoS One. 2013;8:e73638.
16. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;114:457-62.
17. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71:2222-9.
18. Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-Shimon S, Volorio S, et al. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Familial Cancer. 2012;11:483-91.
19. Gonzalez-Hormazabal P, Gutierrez-Enriquez S, Gaete D, Reyes JM, Peralta O, Waugh E, et al. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat. 2011;126:705-16.
20. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc. 2006;1:581-5.
21. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li GL, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A. 2007;104:6788-93.
22. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115.
23. Korkko J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: Comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A. 1998;95:1681-5.
24. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008;66:87-98.
25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-9.
26. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-81.
27. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7:e46688.
28. Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, et al. The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. Familial Cancer. 2013;12:587-95.
29. Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T, et al. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res. 2013;15:R17.
30. Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, et al. Contribution of the PALB2 c.2323C > T [p.Q775X] Founder mutation in well- defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet. 2013;14:5.
31. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet. 2010;11:20.
32. Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, et al. PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat. 2011;126:545-50.
33. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA. PALB2: a novel inactivating mutation in a Italian breast cancer family. Familial Cancer. 2010;9:531-6.
34. Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, et al. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat. 2011;32:E2176-88.
35. Tischkowitz M, Capanu M, Sabbaghian N, Li LL, Liang XL, Vallee MP, et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat. 2012;33:674-80.
36. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat. 2011;127:853-9.
37. Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Familial Cancer. 2010;9:181-5.
38. Peterlongo P, Catucci I, Pasquini G, Verderio P, Peissel B, Barile M, et al. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat. 2011;126:825-8.
39. Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H. PALB2 analysis in BRCA2-like families. Breast Cancer Res Treat. 2011;127:357-62.
40. Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011;126:771-8.
41. Ding YC, Steele L, Chu LH, Kelley K, Davis H, John EM, et al. Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat. 2011;126:227-30.
42. Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, et al. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet. 2009;76:421-6.
43. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137:1183-6.
44. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, et al. PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer. 2011;10:225-31.
45. Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. Familial Cancer. 2009;8:347-53.
46. Blanco A, de la Hoya M, Osorio A, Diez O, Miramar MD, Infante M, et al. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS One. 2013;8:e67538.
47. Garcia MJ, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, et al. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2009;113:545-51.
48. Southey MC, Teo ZL, Winship I. PALB2 and breast cancer: ready for clinical translation! Appl Clin Genet. 2013;6:43-52.
49. Gunnarsson H, Arason A, Gillanders EM, Agnarsson BA, Johannesdottir G, Johannsson OT, et al. Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. J Negat Results Biomed. 2008;7:5.
50. Cruz-Coke R. Ethnic origin and evolution of the Chilean population. Rev Med Chil. 1976;104:365-8.
51. Valenzuela CY, Harb Z. Socioeconomic assortative mating in Santiago, Chile: a demonstration using stochastic matrices of mother-child relationships applied to ABO blood groups. Soc Biol. 1977;24:225-33.
52. Valenzuela CY, Acuna MP, Harb Z. [Sociogenetic gradient in the Chilean population]. Rev Med Chil. 1987;115:295-9.
53. Valenzuela CY, Carvajal T, Marinkovic K. [Differences in hematologic variables according to ABO blood group]. Rev Med Chil. 1988;116:981-4.
54. Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012;118:1362-70.
55. Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:1651-2.
56. Sy SMH, Huen MSY, Chen JJ. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem. 2009;284:21127-31.